Therapy News and Research

RSS

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Santarus, Inc. and Pharming Group NV today announced that the U.S. Food and Drug Administration has accepted for filing the Biologics License Application for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.

18 Jun 2013

Researchers use patient-specific stem cells to correct deficient insulin-producing cells

A team from the New York Stem Cell Foundation Research Institute and the Naomi Berrie Diabetes Center of Columbia University has generated patient-specific beta cells, or insulin-producing cells, that accurately reflect the features of maturity-onset diabetes of the young.

18 Jun 2013

Age disparities exist in continuum of care for patients with HIV

Age disparities exist in the continuum of care for patients with the human immunodeficiency virus (HIV) with people younger than 45 years less likely to be aware of their infection or to have a suppressed viral load, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

18 Jun 2013

Mannitol could prevent aggregation of toxic proteins in the brain, says Tel Aviv University researcher

Mannitol, a sugar alcohol produced by fungi, bacteria, and algae, is a common component of sugar-free gum and candy. The sweetener is also used in the medical field - it's approved by the FDA as a diuretic to flush out excess fluids and used during surgery as a substance that opens the blood/brain barrier to ease the passage of other drugs.

18 Jun 2013

Pyrvinium pamoate inhibits drug-resistant prostate cancer

A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

TSRI scientists identify highly promising new anti-tuberculosis compound

An international team led by scientists at The Scripps Research Institute, the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis bacterium in two different ways.

18 Jun 2013

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

Many men with low-risk, localized prostate cancers can safely choose active surveillance or "watchful waiting" instead of undergoing immediate treatment and have better quality of life while reducing health care costs, according to a study by researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital.

18 Jun 2013

Bazedoxifene used for treating osteoporosis stops growth of breast cancer cells

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.

17 Jun 2013

RetroNectin reagent now available for gene therapy clinical research

In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc. announce the availability of clinical grade RetroNectin reagent for direct supply to biomedical researchers.

17 Jun 2013

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.

17 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Mayo Clinic researchers say that adolescents with chronic pain need to avoid medical marijuana

Adolescents can have chronic pain, just like adults. It can interfere with normal development, making it difficult for teens to attend school, socialize or be physically active, the cause may be hard to find, and medications are sometimes tried without success. As patients, their parents and physicians search for solutions, there is one increasingly available option they should avoid, Mayo Clinic researchers say: medical marijuana.

17 Jun 2013

Investigators recruit subjects for Boston Children's Hand Transplant Program

Boston Children's Hospital today announced that investigators are now recruiting subjects for the world's first pediatric hand transplant program. The Boston Children's Hand Transplant Program, led by principal investigator Amir Taghinia, MD, and William Harmon, MD, is a research-based program that will offer bi-lateral hand transplants for children living without two functioning hands.

17 Jun 2013

KLAS announces 2013 Best in KLAS Awards for medical equipment and infrastructure

KLAS just released the 2013 Best in KLAS Awards: Medical Equipment & Infrastructure report ranking the best-performing imaging, pharmacy automation and infrastructure vendors in the world.

From Elekta 15 Jun 2013

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.

15 Jun 2013

Study shows patients with avascular necrosis have turned to stem cell therapy for aid

Stem cells have long been touted as the next big thing. Well just maybe, it is here. According to Dr. Dennis Lox, some patients with a disorder of the bone called avascular necrosis (AVN), have turned to stem cell therapy for aid.

15 Jun 2013

Dosimetry based on 3-D medical images estimates possible dose for targeted RIT in blood cancer patients

Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art 3D imaging could lead to more personalized and effective treatments to improve patients' chances of living longer without progression of their cancer, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

15 Jun 2013

Lorry driver who developed PTSD after fatal collision receives £220,000

A lorry driver who developed post-traumatic stress disorder after being involved in a fatal collision has received £220,000 in an out of court settlement for his fatal accident claim.

15 Jun 2013

ESH and ESC issue new joint Guidelines for hypertension treatment

Lifestyle factors, lack of awareness by both patients and physicians, hesitancy in initiating and intensifying drug treatment, and healthcare structural deficiencies are amongst the reasons for the increasing problem of high blood pressure in Europe, according to new joint Guidelines issued today by the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC).

15 Jun 2013

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

InterMune, Inc. today announced that the Board of the Italian Drug Agency has approved the pricing and reimbursement conditions for Esbriet (pirfenidone), and that the agreement has been published in the Official Gazette, the official journal of the government of Italy.

15 Jun 2013

Therapy News and Research

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Researchers use patient-specific stem cells to correct deficient insulin-producing cells

Age disparities exist in continuum of care for patients with HIV

Mannitol could prevent aggregation of toxic proteins in the brain, says Tel Aviv University researcher

Pyrvinium pamoate inhibits drug-resistant prostate cancer

TSRI scientists identify highly promising new anti-tuberculosis compound

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

Bazedoxifene used for treating osteoporosis stops growth of breast cancer cells

RetroNectin reagent now available for gene therapy clinical research

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

European Commission amends marketing authorisation for Celgene's REVLIMID

Mayo Clinic researchers say that adolescents with chronic pain need to avoid medical marijuana

Investigators recruit subjects for Boston Children's Hand Transplant Program

KLAS announces 2013 Best in KLAS Awards for medical equipment and infrastructure

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Study shows patients with avascular necrosis have turned to stem cell therapy for aid

Dosimetry based on 3-D medical images estimates possible dose for targeted RIT in blood cancer patients

Lorry driver who developed PTSD after fatal collision receives £220,000

ESH and ESC issue new joint Guidelines for hypertension treatment

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News